Physician profile
Thomas J Haddock
NPI 1255067872
$2,930.96
in general payments reported to CMS, 2019-2025
25 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $287 · 2023: $1,119 · 2024: $952 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $628.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $478.81 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $342.27 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $256.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $228.93 | 2023-2025 | |
| Abbvie INC. | $157.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $115.31 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boston Scientific Corporation | $89.03 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.19 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $66.17 | 2023-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $61.15 | 2022 | |
| Phathom Pharmaceuticals, INC. | $51.22 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $49.62 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $39.04 | 2025 | |
| Halozyme INC | $37.01 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $35.19 | 2023 | Tlando, Xyosted, Nocdurna |
| Merck Sharp & Dohme LLC | $32.72 | 2023 | Belsomra, Verquvo |
| Exact Sciences Corporation | $31.54 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $28.92 | 2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.75 | 2025 | Xifaxan |
| Corcept Therapeutics | $22.32 | 2024 | Korlym |
| Kyowa Kirin, INC. | $21.43 | 2023 | Crysvita |
| Lundbeck LLC | $21.29 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $19.25 | 2023 | Quviviq |
| Dexcom, INC. | $14.81 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Haddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.